SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lupus patients may get new hope for blood pressure control
Disease control Recruiting nowThis study tests whether a supplement called 2-HOBA can help people with lupus by lowering blood pressure and reducing harmful immune activity. About 42 women with stable lupus and mild-to-moderate high blood pressure will take either 2-HOBA or a placebo for 8 weeks, then switch.…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
New antibody aims to tame lupus by targeting troublemaking cells
Disease control Recruiting nowThis early-stage study tests a new drug called HB2198 in 30 adults with moderate to severe lupus, including kidney inflammation. The drug is designed to temporarily remove certain immune cells (B cells) that drive the disease. Participants receive two doses and are monitored for …
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hinge Bio • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Experimental CAR-T therapy targets lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that drive autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusion a…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
Engineered immune cells take on lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 03, 2026 12:05 UTC
-
Blood test could end Trial-and-Error for arthritis patients
Diagnosis Recruiting nowThis study is testing a new blood-based test that aims to predict which medication will work best for each person with an autoimmune rheumatic disease. Researchers will take a blood sample and use it to measure how a patient's immune cells respond to different drugs. If successfu…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Sponsor: University of Bonn • Aim: Diagnosis
Last updated Jun 23, 2026 12:02 UTC
-
New study aims to cut risky pills for seniors with arthritis
Knowledge-focused Recruiting nowThis study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 particip…
Matched conditions: SYSTEMIC LUPUS ERTHEMATOSUS (SLE)
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 23, 2026 15:02 UTC